BioAge Labs (NASDAQ:BIOA) CFO Dov Md Goldstein Sells 27,000 Shares

BioAge Labs, Inc. (NASDAQ:BIOA) CFO Dov Md Goldstein sold 27,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the sale, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BioAge Labs Trading Down 6.2%

Shares of BIOA traded down $1.41 during trading hours on Thursday, reaching $21.51. 885,351 shares of the stock traded hands, compared to its average volume of 1,150,796. BioAge Labs, Inc. has a 52-week low of $2.88 and a 52-week high of $24.00. The company has a market cap of $771.13 million, a P/E ratio of -14.15 and a beta of 1.38. The company’s 50-day moving average price is $11.68 and its two-hundred day moving average price is $7.43.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Analyst Ratings Changes

BIOA has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Citigroup increased their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, BioAge Labs presently has a consensus rating of “Hold” and an average target price of $15.00.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in shares of BioAge Labs by 36.4% in the third quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after buying an additional 4,000 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs during the 3rd quarter worth approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the 2nd quarter valued at $27,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.